10 Sep Exact Sciences Demonstrates Power Of Multi-Cancer Early Detection Approach With Data Presentation At The 2022 European Society For Medical Oncology Congress
Multi-Biomarker Approach Achieves 61 Percent Sensitivity for Cancer at an Overall Specificity of 98.2 Percent in Robust Case-Control Study Including Nearly 600 Cancer Samples
Data will Inform the Largest Registrational Multi-Cancer Early Detection Study Ever Conducted in the United States to Support Another Leading Test in Exact Sciences’ Screening Portfolio
MADISON, Wis., Sept. 10, 2022 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced data from a multi-cancer early detection (MCED) biomarker validation study was presented at the European Society for Medical Oncology (ESMO) Congress. The study rigorously assessed the performance of four distinct biomarker classes found in the blood and known to signal the presence of cancer regardless of its location in the body.
“Cancer releases a diverse set of biomarkers into the blood that can be harnessed to detect the devastating disease at earlier stages,” said Tom Beer, M.D., F.A.C.P., chief medical officer and vice president, multi-cancer early detection, Exact Sciences. “These data demonstrate in a large, well-designed case-control study that combining different cancer biomarkers improves cancer detection, especially in stages I and II, when treatment may be more effective for patients. This is a major step forward in our mission to detect cancer earlier before signs and symptoms appear.”